放射線診断・治療学講座

Keyphrases

1. Carbon Ion Radiotherapy 100%
2. Magnetic Resonance Imaging 82%
3. Apoptosis 72%
4. Ultrasound 62%
5. Induced Apoptosis 60%
6. Tumor 58%
7. Human Leukemia U937 Cells 46%
8. Schizophrenia 44%
9. Hyperthermia 36%
10. Single-photon Emission Computed Tomography (SPECT) 32%
11. U937 Cells 31%
12. Technetium-99m 28%
13. Schizophrenic Patients 28%
14. At-risk Mental State 25%
15. Apparent Diffusion Coefficient 23%
16. Bone Tissue 23%
17. Hyperthermia Induced 22%
18. Lung Cancer 21%
19. Chemotherapy 20%
20. Radiation Therapy 20%
21. 201Tl 20%
22. Head-and-neck 20%
23. Low-intensity Pulsed Ultrasound (LIPUS) 19%
24. Molecular Mechanism 19%
25. X-ray Irradiation 19%
26. Psychosis 19%
27. T2-weighted Imaging (T2WI) 18%
28. Gene Expression 18%
29. First-episode Psychosis 18%
30. Japan 18%
31. Healthy Controls 18%
32. Non-small Cell Lung Cancer (NSCLC) 17%
33. Reactive Oxygen Species 17%
34. Combined Treatment 17%
35. Cell Killing 17%
36. Scintigraphy 17%
37. Apoptosis Induction 17%
38. Overall Survival Rate 16%
39. Schizophrenia Spectrum Disorders 16%
40. Computed Tomography 16%
41. Tc-99m HMPAO 16%
42. Uterine Peristalsis 15%
43. Ultrasound-mediated 15%
44. Uterine Cervical Cancer 15%
45. Magnetic Resonance Imaging Study 15%
46. Ca2+ 14%
47. Soft Tissue Tumor 14%
48. Relative Biological Effectiveness 14%
49. Local Control 14%
50. Signal Intensity 14%
51. Oxime 14%
52. Oxidative Stress 14%
53. Regional Cerebral Blood Flow (rCBF) 14%
54. Moyamoya Disease 14%
55. Radiotherapy 14%
56. Irradiation 13%
57. Diffusion-weighted Imaging 13%
58. Hypofractionation 13%
59. Prostate Cancer 13%
60. HeLa Cells 13%
61. Treatment Planning 13%
62. Stage I Lung Cancer 13%
63. Radiation-induced Apoptosis 13%
64. Brain Perfusion 13%
65. Cancer Cells 12%
66. Patients with Schizophrenia 12%
67. Intracellular Reactive Oxygen Species 12%
68. Chemoradiotherapy 12%
69. Reactive Oxygen Species Production 12%
70. Clinical Outcomes 12%
71. Uterus 12%
72. Cell Death 12%
73. DNA Fragmentation 12%
74. Clinical High Risk for Psychosis (CHR-P) 12%
75. Fluid-attenuated Inversion Recovery (FLAIR) 11%
76. Mitochondrial Membrane Potential 11%
77. Mitochondria 11%
78. Gene Transfection 11%
79. Prospective Observational Study 11%
80. Caspase-3 11%
81. Cold Atmospheric Plasma 11%
82. Gene Regulation 10%
83. Echo Contrast 10%
84. Contrast Agent 10%
85. Cervical Cancer 10%
86. X-ray 10%
87. Neck Tumor 10%
88. Radiation Effects 10%
89. Luciferase Activity 10%
90. HDR Brachytherapy 10%
91. Cerebral Blood Flow 10%
92. Oncology Studies 10%
93. Radiation Oncology 10%
94. Apoptotic Pathway 10%
95. Luciferase Gene 10%
96. Doxorubicin 10%
97. In Cancer 10%
98. Amines 9%
99. Preoperative Chemotherapy 9%
100. Total Dose 9%

Medicine and Dentistry

1. Neoplasm 99%
2. Ion Therapy 91%
3. Magnetic Resonance Imaging 79%
4. Radiation Therapy 43%
5. Lung Cancer 32%
6. Single-Photon Emission Computed Tomography 32%
7. Scintigraphy 32%
8. Cervical Cancer 27%
9. Computer Assisted Tomography 25%
10. Thallium 201 24%
11. Overall Survival 24%
12. Neck 24%
13. Programmed Cell Death 23%
14. Recurrent Disease 23%
15. Non Small Cell Lung Cancer 22%
16. Chemotherapy 22%
17. Disease 21%
18. Bone Tissue 21%
19. Survival Rate 21%
20. Relative Biologic Effectiveness 21%
21. Magnetic Resonance Imaging 19%
22. Diffusion MRI 19%
23. Positron Emission Tomography 18%
24. Adverse Event 18%
25. Squamous Cell Carcinoma 18%
26. Technetium-99 17%
27. Peristalsis 15%
28. Treatment Planning 15%
29. Metastatic Carcinoma 15%
30. Soft Tissue Tumor 14%
31. Malignant Neoplasm 14%
32. Pelvis 13%
33. Prostate Cancer 13%
34. U937 Cell 13%
35. Brain Metastasis 12%
36. Free Radical 12%
37. Chemoradiotherapy 11%
38. Carotid Artery Stenosis 11%
39. Adenocarcinoma 11%
40. Bleeding 10%
41. Observational Study 10%
42. Head and Neck Tumor 10%
43. Uterine Cancer 10%
44. Retrospective Study 10%
45. Progression Free Survival 10%
46. Radiation Oncology 10%
47. Fluorodeoxyglucose 10%
48. Mucositis 9%
49. Dose-Volume Histogram 9%
50. Moyamoya Disease 9%
51. Positron Emission Tomography-Computed Tomography 9%
52. Iodine 123 9%
53. Lymph Node Metastasis 8%
54. In Vitro 8%
55. Necrosis 8%
56. Edema 8%
57. MALT Lymphoma 8%
58. Intensity Modulated Radiation Therapy 8%
59. Lung 8%
60. Diagnosis 8%
61. Fluorodeoxyglucose F 18 8%
62. Head and Neck Cancer 8%
63. Osteosarcoma 8%
64. External Beam Radiotherapy 8%
65. Brachytherapy 8%
66. Reactive Oxygen Species 8%
67. Surgery 8%
68. Myometrium 7%
69. Infarction 7%
70. Steady State 7%
71. Multivariate Analysis 7%
72. Mucosal Melanoma 7%
73. Hyperthermia 7%
74. Drug Megadose 7%
75. Cine Magnetic Resonance Imaging 7%
76. Stereotactic Body Radiation Therapy 7%
77. Hexamethylpropylene Amine Oxime Technetium Tc 99m 7%
78. Magnetic Resonance Angiography 7%
79. High-Dose-Rate Brachytherapy 7%
80. Preoperative Chemotherapy 7%
81. Carotid Endarterectomy 7%
82. Apoplexy 7%
83. Radiology 6%
84. Obstetrics 6%
85. Cancer Cell 6%
86. Rectum Cancer 6%
87. Artery 6%
88. Cancer 6%
89. Gynecology 6%
90. Cylindroma 6%
91. Brain Blood Flow 6%
92. Cell Killing 6%
93. Microvessel 6%
94. Prospective Study 6%
95. Genetic Transfection 5%
96. Pulse Rate 5%
97. Dural Arteriovenous Fistula 5%
98. Single Drug Dose 5%
99. Low-Intensity Pulsed Ultrasound 5%
100. Breast Cancer 5%